Torno Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Torno Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-4,000	Closed	-$1.86M	–	258
2024 Q3	$1.86M	Sell	4,000 -4,720	-54%	-$2.27M	0.28%	73
2024 Q2	$4.09M	Sell	8,720 -29,530	-77%	-$12.8M	0.19%	49
2024 Q1	$16M	Buy	+38,250	New	+$16.2M	1.02%	25

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Torno Capital's VRTX Position: Q4 2024 in Review

Torno Capital sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 4,000 shares — an estimated $1.86M sold.

Torno Capital first reported a position in VRTX in Q1 2024 and held it in 3 quarters. The position peaked at $16M in Q1 2024. 1,562 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

Torno Capital reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Torno Capital sold 4,000 Vertex Pharmaceuticals shares in Q4 2024, an estimated $1.86M.
Torno Capital first reported a position in Vertex Pharmaceuticals in Q1 2024 and held it in 3 quarters.
Torno Capital's Vertex Pharmaceuticals position peaked at $16M in Q1 2024.
1,562 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on Torno Capital's 13F filing for Q4 2024, filed 14 Feb 2025.